Liver enzyme levels in adolescent patients treated with buprenorphine and additional psychotropic agents

Basit Öğe Kaydı
dc.contributor.authorDemirci, Arzu Çiftçi
dc.contributor.authorGüneş, Hatice
dc.contributor.authorAdaletli, Hilal
dc.contributor.authorBulanık, Esra
dc.contributor.authorErdoğan, Ayten
dc.date.accessioned2020-04-30T23:18:57Z
dc.date.available2020-04-30T23:18:57Z
dc.date.issued2015
dc.departmentDÜ, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümüen_US
dc.descriptionWOS: 000346073600015en_US
dc.descriptionPubMed: 25490611en_US
dc.description.abstractBackground: There are limited efficacy and safety data for buprenorphine/naloxone treatment in adolescents, and little is known about the incidence and prevalence of liver function abnormalities in young patients using buprenorphine/naloxone. Objectives: To assess the changes in liver enzyme levels associated with buprenorphine/naloxone treatment and co-medication with psychotropic agents among opioid dependent subjects aged 15-18 years. Methods: Liver enzyme levels (ALT and AST) were evaluated among 59 adolescent subjects before and following eight weeks of buprenorphine/naloxone treatment. Results: The frequency of additional psychotropic use was 60%. The patients' mean liver enzyme levels at weeks 2 and 4 were significantly higher than the baseline (ALT: p<0.0001 and p = 0.003, and AST: p<0.0001 and p = 0.016, respectively). However, there was no statistically significant difference in AST and ALT levels between the baseline and week 8. The majority of the abnormalities seen were clinically nonsignificant elevations (less than two times the upper limit of normal). It is plausible that the abnormalities in liver enzymes could have been mediated by the use of psychotropic medications. Conclusions: Buprenorphine/naloxone was well tolerated in most adolescent patients, besides clinically nonsignificant liver enzyme elevations. Psychotropic medications may have been associated with the liver enzyme changes early in the course of treatment. Nevertheless, given the relatively small number of adolescents studied to date with buprenorphine/naloxone, additional studies evaluating liver enzymes in young patients receiving buprenorphine/naloxone (and no other psychotropics) are needed.en_US
dc.identifier.doi10.3109/00952990.2014.983272en_US
dc.identifier.endpage113en_US
dc.identifier.issn0095-2990
dc.identifier.issn1097-9891
dc.identifier.issue1en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage107en_US
dc.identifier.urihttps://doi.org/10.3109/00952990.2014.983272
dc.identifier.urihttps://hdl.handle.net/20.500.12684/3595
dc.identifier.volume41en_US
dc.identifier.wosWOS:000346073600015en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakPubMeden_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherTaylor & Francis Incen_US
dc.relation.ispartofAmerican Journal Of Drug And Alcohol Abuseen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectAdolescenten_US
dc.subjectbuprenorphineen_US
dc.subjectheroinen_US
dc.subjectliver enzymesen_US
dc.subjectnaloxoneen_US
dc.subjectopioid useen_US
dc.titleLiver enzyme levels in adolescent patients treated with buprenorphine and additional psychotropic agentsen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
3595.pdf
Boyut:
245.16 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Makale Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu

We collect and process your personal information for the following purposes: Authentication, Preferences, Acknowledgement and Statistics.
To learn more, please read our privacy policy.

Customize